EU regulator backs GSK’s rubella virus vaccine for use in adults aged 50-59 years
The European Union’s health regulator has recommended expanding the use of GSK’s respiratory syncytial virus (RSV) vaccine to adults aged 50-59 years. The vaccine, called Arexvy, was approved by the US Food and Drug Administration in June.
ПОПУЛЯРНЫЕ ПОСТЫ
Poland prepares for peaking floods
Сентябрь 20, 2024
Italy evacuates thousands as Boris hits the north
Сентябрь 20, 2024
China and the US race to tame nuclear fusion for clean energy
Сентябрь 20, 2024
ПОДПИСЫВАЙТЕСЬ НА НАС
ПРЯМАЯ ТРАНСЛЯЦИЯ